Rep. Robert Bresnahan, Jr. Purchases Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of West Pharmaceutical Services, Inc. (NYSE:WST). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in West Pharmaceutical Services stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

West Pharmaceutical Services Price Performance

WST stock traded down $3.98 during midday trading on Friday, reaching $222.08. The company had a trading volume of 496,755 shares, compared to its average volume of 664,265. The stock has a 50 day moving average price of $263.98 and a 200-day moving average price of $297.82. The company has a market capitalization of $16.06 billion, a price-to-earnings ratio of 33.20, a price-to-earnings-growth ratio of 6.74 and a beta of 1.09. West Pharmaceutical Services, Inc. has a 1-year low of $197.01 and a 1-year high of $396.75. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.75 by $0.07. The firm had revenue of $748.80 million during the quarter, compared to analyst estimates of $739.59 million. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. Equities research analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date of this dividend is Wednesday, April 30th. West Pharmaceutical Services’s payout ratio is currently 12.56%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of WST. Quadrant Capital Group LLC boosted its position in West Pharmaceutical Services by 5.4% during the 4th quarter. Quadrant Capital Group LLC now owns 626 shares of the medical instruments supplier’s stock worth $205,000 after acquiring an additional 32 shares during the last quarter. Baron Wealth Management LLC boosted its position in West Pharmaceutical Services by 1.9% in the fourth quarter. Baron Wealth Management LLC now owns 1,926 shares of the medical instruments supplier’s stock valued at $631,000 after buying an additional 35 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in shares of West Pharmaceutical Services by 18.9% during the fourth quarter. Exchange Traded Concepts LLC now owns 239 shares of the medical instruments supplier’s stock valued at $78,000 after buying an additional 38 shares during the last quarter. Lake Street Advisors Group LLC raised its position in shares of West Pharmaceutical Services by 5.8% in the fourth quarter. Lake Street Advisors Group LLC now owns 711 shares of the medical instruments supplier’s stock valued at $233,000 after purchasing an additional 39 shares during the period. Finally, Cornerstone Planning Group LLC lifted its holdings in shares of West Pharmaceutical Services by 57.1% during the 4th quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 40 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on WST shares. KeyCorp dropped their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Evercore ISI assumed coverage on shares of West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an “outperform” rating and a $275.00 target price on the stock. Bank of America upped their price objective on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. StockNews.com cut West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price on the stock in a research report on Friday, February 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $332.50.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.